Shots:

• Merck acquires Immune Design- in all stock transaction for $5.85/share in cash making total deal value ~ $300M. The transaction is expected to close in Q2’19
• The focus of the agreement is to develop and commercialize immune vaccines using Immune Design’s in vivo technologies i.e GLAAS and ZVex against cancer and infectious diseases
• GLA Adjuvant Systems (GLAAS) is an in vivo Glucopyranosyl Lipid A (GLA) based platform that binds TLR4 receptor activating DCs to produce cytokines and chemokines activating Th1-type immune response. ZVex is a delivery system designed for developing T-Cells targeting tumor cells  

Ref: Merck | Image: Merck